For US Healthcare Professionals Only
Filter
Concomitant use of glucagon-like peptide-1 receptor agonists in patients with psoriasis or hidradenitis suppurativa receiving bimekizumab: Cross-sectional analysis of US claims data
Bimekizumab and other biologics for moderate to severe psoriasis: Systematic literature review and meta-analysis of real-world PASI 100 response over time
Bimekizumab improves draining tunnel outcomes in patients with moderate to severe HS regardless of prior biologic use: 3-year data from BE HEARD EXT
Sex-specific and age-adjusted prevalence of hidradenitis suppurativa: Results from Komodo US claims data suggest sex parity of HS symptoms
Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study
Empowering Psoriasis Shared Decision-Making With Digital Tools
Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment
Bimekizumab Leads to Sustained Flare-Free Status in Moderate to Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT
Retrospective Observation of Liver Function Tests in Patients Receiving Biologic or Targeted Oral Systemic Treatments with Psoriasis, Psoriatic Arthritis, and/or Hidradenitis Suppurativa
Social Determinants of Health of Patients Living with Hidradenitis Suppurativa in Rural Versus Urban United States